TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04858334: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BR

Sponsor: National Cancer Institute (NCI) · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 152 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT04858334 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04858334 Rescue Dossier →